Skip to main navigation Skip to search Skip to main content

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

Christoph Heesen*, Ingo Kleiter, Sven G. Meuth, Julia Krämer, Jürgen Kasper, Sascha Köpke, Wolfgang Gaissmaier

*Corresponding author for this work
24   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients'. Together they form a unique fingerprint.
Sort by

Neuroscience